6. パーキンソン病 Parkinson disease Clinical trials / Disease details


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

  
13 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-002754-24-DE
(EUCTR)
19/01/202214/06/2021Clinical study in early PD patients to investigate the effect of Opicapone 50mg or Levodopa 100 mg in the treatment of motor fluctuations.A randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study to evaluate the add-on effect of opicapone 50 mg or levodopa 100 mg as first strategy for the treatment of wearing-off in patients with Parkinson’s Disease. - ADOPTION: eArly levoDopa with Opicapone in Parkinson’s paTients wIth motOr fluctuatioNs Parkinson's Disease (PD)
MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Ongentys 50 mg hard capsules
INN or Proposed INN: Ongentys 50 mg hard capsules
Other descriptive name: OPICAPONE
Trade Name: Madopar 125 mg T, tablets
INN or Proposed INN: BENSERAZIDE HYDROCHLORIDE
INN or Proposed INN: LEVODOPA
Other descriptive name: LEVODOPA
Trade Name: SINEMET 100 mg + 25 mg tablets
INN or Proposed INN: LEVODOPA
Other descriptive name: LEVODOPA
INN or Proposed INN: CARBIDOPA
Other descriptive name: CARBIDOPA
Bial - Portela & Ca, S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 4Portugal;Spain;Germany;United Kingdom;Italy
2NCT04990284
(ClinicalTrials.gov)
November 29, 202127/7/2021eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.A Randomized, Parallel Group, Multicentre, Multinational, Prospective, Open-label Exploratory Study to Evaluate the add-on Effect of Opicapone 50 mg or Levodopa 100 mg as First Strategy for the Treatment of Wearing-off in Patients With Parkinson's Disease.Parkinson DiseaseDrug: Opicapone;Drug: L-DOPA/DDCIBial - Portela C S.A.NULLRecruiting30 YearsN/AAll100Phase 4Germany;Italy;Portugal;Spain;United Kingdom
3EUCTR2020-002754-24-IT
(EUCTR)
09/09/202130/08/2021Clinical study in early PD patients to investigate the effect of Opicapone 50mg or Levodopa 100 mg in the treatment of motor fluctuations.A randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study to evaluate the add-on effect of opicapone 50 mg or levodopa 100 mg as first strategy for the treatment of wearing-off in patients with Parkinson's Disease. - ADOPTION: eArly levoDopa with Opicapone in Parkinson's paTients wIth motOr fluctuatioNs Parkinson's Disease (PD)
MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: SINEMET 100 mg + 25 mg tablets
Product Name: SINEMET 100 mg + 25 mg compresse
Product Code: [023145028]
INN or Proposed INN: Levodopa
Other descriptive name: Levodopa
INN or Proposed INN: Carbidopa
Other descriptive name: Carbidopa
Trade Name: Madopar 125 mg T, tablets
Product Name: Madopar® 125 mg T Tablets Levodopa 100 mg Benserazide 25 mg (as benserazide hydrochloride)
Product Code: [6036937.00.01]
INN or Proposed INN: BENSERAZIDE HYDROCHLORIDE
INN or Proposed INN: Levodopa
Other descriptive name: Levodopa
Trade Name: Ongentys 50 mg hard capsules
Product Name: Ongentys 50 mg capsule rigide
Product Code: [BIA 9-1067]
INN or Proposed INN: Opicapone
Other descriptive name: Opicapone
BIAL-Portela & Ca, S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 4Portugal;Spain;Germany;United Kingdom;Italy
4EUCTR2020-002754-24-ES
(EUCTR)
06/07/202109/06/2021Clinical study in early PD patients to investigate the effect of Opicapone 50mg or Levodopa 100 mg in the treatment of motor fluctuations.A randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study to evaluate the add-on effect of opicapone 50 mg or levodopa 100 mg as first strategy for the treatment of wearing-off in patients with Parkinson’s Disease. - ADOPTION: eArly levoDopa with Opicapone in Parkinson’s paTients wIth motOr fluctuatioNs Parkinson's Disease (PD)
MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Ongentys 50 mg hard capsules
INN or Proposed INN: Ongentys 50 mg hard capsules
Other descriptive name: OPICAPONE
Trade Name: Madopar 125 mg T, tablets
INN or Proposed INN: BENSERAZIDE HYDROCHLORIDE
INN or Proposed INN: LEVODOPA
Other descriptive name: LEVODOPA
Trade Name: SINEMET 100 mg + 25 mg tablets
INN or Proposed INN: LEVODOPA
Other descriptive name: LEVODOPA
INN or Proposed INN: CARBIDOPA
Other descriptive name: CARBIDOPA
Bial - Portela & Ca, S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 4Portugal;Spain;Germany;United Kingdom;Italy
5NCT04821687
(ClinicalTrials.gov)
June 17, 202125/3/2021A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PDA Randomized, Parallel Group, Multicenter, Prospective, Open-label, Exploratory, Phase 4 Study to Evaluate the Add-on Effect of Opicapone 50 mg or Levodopa 100 mg as First Strategy for the Treatment of Wearing-off in Patients With Parkinson's DiseaseParkinson DiseaseDrug: Ongentys 50mg;Drug: Madopar Tab. 125 or Perkin Tab. 25-100mgSK Chemicals Co., Ltd.NULLRecruiting30 YearsN/AAll200Phase 4Korea, Republic of
6NCT04986995
(ClinicalTrials.gov)
June 9, 202127/7/2021OpicApone Sleep dISorderOpen-label, Single-arm, Pilot Study to Evaluate the Effect of Opicapone 50 mg on Parkinson's Disease Patients With End-of-dose Motor Fluctuations and Associated Sleep DisordersParkinson DiseaseDrug: OpicaponeBial - Portela C S.A.NULLRecruiting30 YearsN/AAll30Phase 4Portugal
7NCT04978597
(ClinicalTrials.gov)
May 31, 20215/7/2021Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel-Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add-on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson's Disease Patients, With an Open-Label ExtensionParkinsonDrug: Opicapone 50 mg;Drug: PlaceboBial - Portela C S.A.NULLRecruiting30 Years80 YearsAll324Phase 3Bulgaria
8EUCTR2020-001176-15-DE
(EUCTR)
07/05/202117/12/2020Clinical study to investigate if Opicapone 50mg can reduce sleep disorders associated to Parkinson's disease.Open-label, single-arm, pilot study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated sleep disorders. - OpicApone Sleep dISorder (OASIS) Parkinson's disease patients with wearing-off motor fluctuations and associated sleep disorders.
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Ongentys
Product Name: Ongentys 50 mg hard capsules
INN or Proposed INN: OPICAPONE
Other descriptive name: OPICAPONE
Bial - Portela & Ca, S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Phase 4Portugal;Germany
9EUCTR2020-001176-15-PT
(EUCTR)
19/03/202104/01/2021Clinical study to investigate if Opicapone 50mg can reduce sleep disorders associated to Parkinson's disease.Open-label, single-arm, pilot study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated sleep disorders. - OpicApone Sleep dISorder (OASIS) Parkinson's disease patients with wearing-off motor fluctuations and associated sleep disorders.
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Ongentys
Product Name: Ongentys 50 mg hard capsules
INN or Proposed INN: OPICAPONE
Other descriptive name: OPICAPONE
Bial - Portela & Ca, S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Phase 4Portugal;Germany
10NCT04986982
(ClinicalTrials.gov)
February 25, 202127/7/2021OpiCapone Effect on Motor Fluctuations and pAiNRandomised, Double-blind, Placebo-controlled, Clinical Study to Evaluate the Effect of Opicapone 50 mg on Parkinson's Disease Patients With End-of-dose Motor Fluctuations and Associated Pain.Parkinson DiseaseDrug: Opicapone 50 mg;Other: Matching placeboBial - Portela C S.A.NULLRecruiting30 YearsN/AAll140Phase 4United Kingdom
11EUCTR2020-001175-32-PT
(EUCTR)
15/01/202130/09/2020Clinical study to investigate if Opicapone 50mg can reduce pain associated to Parkinson’s diseaseRandomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated pain. - OpiCapone Effect on motor fluctuations and pAiN (OCEAN) Parkinson's disease patients with wearing-off motor fluctuations and associated pain.
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Ongentys
Product Name: Opicapone 50 mg hard capsules
INN or Proposed INN: Opicapone
Bial - Portela & Ca, S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
176Phase 4Portugal;Spain;Germany;United Kingdom;Italy
12EUCTR2020-001175-32-IT
(EUCTR)
17/12/202015/06/2021Clinical study to investigate if Opicapone 50mg can reduce pain associated to Parkinson's diseaseRandomized, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson's disease patients with end-of-dose motor fluctuations and associated pain. - OpiCapone Effect on motor fluctuations and pAiN (OCEAN) Parkinson's disease patients with wearing-off motor fluctuations and associated pain.
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Ongentys
Product Name: Ongentys 50 mg capsule rigide
Product Code: [BIA 9-1067]
INN or Proposed INN: Opicapone
BIAL-Portela & Ca, S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
176Phase 4Portugal;Spain;Germany;United Kingdom;Italy
13EUCTR2020-001175-32-GB
(EUCTR)
29/09/202007/08/2020Clinical study to evaluate the effect of opicapone 50 mg in the pain associated to Parkinson’s disease.Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated pain. - OpiCapone Effect on motor fluctuations and pAiN (OCEAN) Parkinson's disease patients with wearing-off motor fluctuations andassociated pain.
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Ongentys
Product Name: Ongentys
INN or Proposed INN: Opicapone
Bial - Portela & Ca, S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
176Phase 4Portugal;Spain;Germany;Italy;United Kingdom